-+ 0.00%
-+ 0.00%
-+ 0.00%
12 Health Care Stocks Moving In Wednesday's After-Market Session
Share
Listen to the news

Gainers

  • Nanobiotix (NASDAQ:NBTX) shares rose 60.8% to $17.0 during Wednesday's after-market session. The company's market cap stands at $469.6 million.
  • AquaBounty Techs (NASDAQ:AQB) stock moved upwards by 48.24% to $1.69. The market value of their outstanding shares is at $4.3 million.
  • rYojbaba (NASDAQ:RYOJ) shares increased by 14.07% to $2.35. The company's market cap stands at $25.2 million.
  • Bone Biologics (NASDAQ:BBLG) stock moved upwards by 11.84% to $2.36. The market value of their outstanding shares is at $3.4 million.
  • Cadrenal Therapeutics (NASDAQ:CVKD) shares increased by 7.99% to $13.65. The company's market cap stands at $27.3 million.
  • Tectonic Therapeutic (NASDAQ:TECX) stock increased by 6.57% to $16.05. The market value of their outstanding shares is at $299.5 million.

Losers

  • Helius Medical Tech (NASDAQ:HSDT) shares fell 7.7% to $21.0 during Wednesday's after-market session. The market value of their outstanding shares is at $24.0 million.
  • Qualigen Therapeutics (NASDAQ:QLGN) shares decreased by 6.12% to $2.12. The company's market cap stands at $3.3 million.
  • Ocugen (NASDAQ:OCGN) stock fell 6.07% to $1.24. The company's market cap stands at $365.3 million.
  • Entero Therapeutics (NASDAQ:ENTO) shares fell 5.8% to $4.5. The market value of their outstanding shares is at $6.4 million.
  • China SXT Pharmaceuticals (NASDAQ:SXTC) stock fell 5.1% to $1.86. The market value of their outstanding shares is at $216.9 million.
  • Indaptus Therapeutics (NASDAQ:INDP) stock declined by 5.07% to $2.25. The market value of their outstanding shares is at $2.6 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending